Anidulafungin treatment of candidal central nervous system infection in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3576-3578

  Kang, Cheol In ^a,b   Rouse, Mark S ^b   Mandrekar, Jayawant N ^c   Steckelberg, James M ^b   Patel, Robin ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CANDIDA ALBICANS; CENTRAL NERVOUS SYSTEM CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTIONS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; MICE; PYRIMIDINES; TRIAZOLES;

EID: 67749084491     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00646-09     Document Type: Article

References (16)

1. Andes, D., D. J. Diekema, M. A. Pfaller, R. A. Prince, K. Marchillo, J. Ashbeck, and J. Hou. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
2. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
3. Graybill, J. R., L. K. Najvar, G. M. Gonzalez, S. Hernandez, and R. Bocanegra. 2003. Improving the mouse model for studying the efficacy of voriconazole. J. Antimicrob. Chemother. 51:1373-1376.
4. Gumbo, T., G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50:3695-3700.
5. Hope, W. W., D. Mickiene, V. Petraitis, R. Petraitiene, A. M. Kelaher, J. E. Hughes, M. P. Cotton, J. Bacher, J. J. Keirns, D. Buell, G. Heresi, D. K. Benjamin, Jr., A. H. Groll, G. L. Drusano, and T. J. Walsh. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197:163-171.
6. Klein, M., B. Obermaier, B. Angele, H. W. Pfister, H. Wagner, U. Koedel, and C. J. Kirschning. 2008. Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. J. Infect. Dis. 198:1028-1036.
7. Lachin, J. M. 1999. Worst-rank score analysis with informatively missing observations in clinical trials. Control. Clin. Trials 20:408-422.
8. Mook-Kanamori, B. B., M. S. Rouse, C. I. Kang, D. van de Beek, J. M. Steckelberg, and R. Patel. 2009. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect. Dis. 9:50.
9. Parker, J. C., Jr., J. J. McCloskey, and R. S. Lee. 1981. Human cerebral candidosis - a postmortem evaluation of 19 patients. Hum. Pathol. 12:23-28.
10. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
11. Sánchez-Portocarrero, J., E. Perez-Cecilia, O. Corral, J. Romero-Vivas, and J. J. Picazo. 2000. The central nervous system and infection by Candida species. Diagn. Microbiol. Infect. Dis. 37:169-179.
12. Serena, C., F. J. Pastor, M. Marine, M. M. Rodriguez, and J. Guarro. 2007. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J. Antimicrob. Chemother. 60:162-165.
13. Shih, W. 2002. Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control. Trials Cardiovasc. Med. 3:4.
14. Shuford, J. A., M. S. Rouse, K. E. Piper, J. M. Steckelberg, and R. Patel. 2006. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194:710-713.
15. Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.
16. Zornes, L. L., and R. E. Stratford. 1997. Development of a plasma highperformance liquid chromatographic assay for LY303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study. J. Chromatogr. B Biomed. Sci. Appl. 695:381-387.